Associate Professor Herbert Ho Fung LOONG - 香港中文大學學術研究文庫

龍浩鋒教授

個人資料

職位/學系

副教授, 腫瘤學系

ORCiD0000-0002-6607-1106

中大研究成果

1/5

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease (2024)

Can ChatGPT Provide Quality Information on Integrative Oncology? A Brief Report (2024)

Impact of Body Image Perception on Behavioral Outcomes in Chinese Adolescent and Young Adult Survivors of Sarcoma (2024)

Perception of Online Communities towards the Use of Cancer Immunotherapy: A Data Mining Study of 3.6 Million Web-based Posts from Social Media Platforms (2024)

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study) (2023)

Association between potential supplement–drug interactions and liver diseases in patients with cancer: A large prospective cohort study (2023)

Associations between Lifestyle Factors and Neurocognitive Impairment among Chinese Adolescent and Young Adult (AYA) Survivors of Sarcoma in Hong Kong (2023)

Associations between Lifestyle Factors and Neurocognitive Impairment among Chinese Adolescent and Young Adult (AYA) Survivors of Sarcoma (2023)

Associations of dietary supplement use with all-cause and cause-specific mortality in patients diagnosed with cancer: a large prospective cohort study in the UK Biobank (2023)

Best Clinical Management of Tenosynovial Giant Cell Tumour (TGCT): A Consensus Paper From the Community of Experts (2023)

Consensus Statements on Precision Oncology in the China Greater Bay Area (2023)

Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases (2023)

Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088 (2023)

Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas (2023)

First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors (2023)

Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong's healthcare system (2023)

Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib (2023)

Global Health System Resilience during Encounters with Stressors - Lessons Learnt from Cancer Services during the COVID-19 Pandemic (2023)

Immune-related Adverse Events Associated with PD-1/PD-L1 Inhibitors in Metastatic NSCLC Patients: A Single-Center Study from Hong Kong (2023)

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC) (2023)

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS(G12C) inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC (2023)

MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK) (2023)

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors (2023)

NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours (2023)

Online Discussions on Traditional, Complementary, and Integrative Medicine among Patients with Cancer: A Data-Mining Study of Health Forums and Social Media (2023)

Oral capecitabine or tegafur/gimeracil/oteracil as induction and adjuvant/maintenance chemotherapy in the management of stage III-IVb nasopharyngeal carcinoma: A systematic-review and meta-analysis (2023)

Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period (2023)

Potential supplement-drug interactions in the liver among patients with cancer and their association with hepatic conditions: a UK Biobank study (2023)

Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC (2023)

Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group (2023)

Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD (2023)

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial (2023)

The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours (2023)

The Mediatory Role of Cancer-related Symptoms in Cognitive Complaints among Adolescents and Young Adults (AYAs) with Cancer (2023)

The Use of Traditional, Complementary, and Integrative Medicine in Cancer: Data-Mining Study of 1 Million Web-Based Posts From Health Forums and Social Media Platforms (2023)

The use of traditional, complementary and integrative medicine in Chinese adolescent and young adult patients with cancer: A multicenter cross-sectional study (2023)

The use of traditional, complementary and integrative medicine in Chinese adolescents and young adults patients with cancer: a multi-center study (2023)

Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/ metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC) (2023)

362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial (2022)

Adjunctive PD-1 inhibitor versus standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis (2022)

Association of supplement use with all-cause and cause-specific mortality in cancer: UK Biobank study (2022)

Cancer-related symptoms as mediators between treatment and functional capacity in adolescents and young adults (AYAs) with cancer (2022)

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia (2022)

ClinMatch: A clinical trial matching platform that improves trial accessibility among NSCLC patients through comprehensive genomic and clinical profiling (2022)

Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication (2022)

Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901) (2022)

Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations (2022)

Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC) (2022)

Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours (2022)

Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis (2022)

Most Relevant Area

Oncology (Internal medicine related)

分享連結

Our policy towards the use of cookies